CAC
BMY.RT

Cowen and Company’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Cowen and Company’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-350,000
Closed -$242K – 760
2020
Q4 		$242K Buy
+350,000
New +$746K 0.02% 166
2020
Q2 		– Sell
-50,000
Closed -$190K – 533
2020
Q1 		$190K Buy
50,000
+18,795
+60% +$61.9K 0.04% 199
2019
Q4 		$94K Buy
+31,205
New +$81.1K 0.01% 269

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Cowen and Company's BMY.RT Position: Q1 2021 in Review

Cowen and Company sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 350,000 shares — an estimated $242K sold.

Cowen and Company first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $242K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Cowen and Company reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Cowen and Company sold 350,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $242K.
  • Cowen and Company first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Cowen and Company's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $242K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Cowen and Company's 13F filing for Q1 2021, filed 4 May 2021.